Web Analytics

3 Latest Announced Rounds

  • $7,000,000
    Seed

    1 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,300,000
    Pre-Seed

    7 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,800,000
    Seed

    4 Investors

    Software Development
    Apr 12th, 2024
$1,933.10M Raised in 90 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Kiyatec Inc.

start up
United States - Greenville, SC
  • 19/05/2023
  • Unknown
  • Undisclosed Amount

Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins.

We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality.

Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com


Related People

Matt GevaertFounder

Matt Gevaert United States - Greenville, South Carolina

Passionately building a world where patients with brain cancer, ovarian cancer, and more indications to come respond to the drugs they are treated with, through accurate prediction of their individual responses prior to treatment.

Dr. Matthew (Matt) Gevaert is the Chief Executive Officer, a Co-Founder and a Board Member of Kiyatec, Inc.

Under Matt’s leadership Kiyatec is disrupting cancer therapy selection with patient-specific prediction of response to drug therapies, prior to treatment. Kiyatec achieves this by measuring the response of individual patient live cancer cells with its innovative 3D cell culture technology platform, with success demonstrated in peer-reviewed publications for multiple tumor types that score >95th percentile in on-line impact.

Through a dedicated focus on direct relevance to cancer patients, Kiyatec has successfully attracted multiple rounds of private sector investment, developed its 3D Predict™ and KIYA-Predict™ ex vivo 3D cell culture platforms, and published the first functional precision oncology assay with clinically-correlated prospective predictive therapeutic response evidence in multiple tumor types.

To-date, Kiyatec has been awarded more than $5M of competitively awarded federal funding including contracts from the National Cancer Institute, cultivated clinical collaborations at leading national cancer institutions and built productive relationships with premier biopharmaceutical companies developing the cancer therapies of the future.

Matt is a graduate of the University of Waterloo (B.Sc., Chemistry) and of Clemson University (M.S. and Ph.D., Bioengineering). He serves on a number of professional and community boards and occasionally teaches an MBA graduate course in technology entrepreneurship for professional business students.